A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan

OBJECTIVE: Treatment options for HER-2-positive metastatic breast cancer (mBC) patients have expanded markedly since trastuzumab approval in 1998. Several other regimens are now available, including pertuzumab plus trastuzumab plus docetaxel, T-DM1, capecitabine plus lapatinib, and trastuzumab plus...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast
Autors principals: Diaby, Vakaramoko, Alqhtani, Hussain, van Boemmel-Wegmann, Sascha, Wang, Ching-Yu, Ali, Askal Ayalew, Balkrishnan, Rajesh, Ko, Yu, Palacio, Sofia, de Lima Lopes, Gilberto
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7375554/
https://ncbi.nlm.nih.gov/pubmed/31805500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2019.11.012
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars